• Policy
• LG Chem and Samsung Bioepis's biosimilars are reimbursed
• by Lee, Tak-Sun Jun 25, 2024 05:46am

• Policy
• Combinatory drugs with linagliptin+dapagliflozin
• by Lee, Tak-Sun Jun 25, 2024 05:46am

• Opinion
• [Reporter's View] No more exemptions, just deferrals
• by Eo, Yun-Ho Jun 24, 2024 05:47am

• Policy
• Will GMP One-strike-out be loosened?...MFDS, 'negative'
• by Lee, Hye-Kyung Jun 24, 2024 05:47am

• Company
• K-Bios make bid into pancreatic cancer treatment environment
• by Son, Hyung-Min Jun 24, 2024 05:47am

• Policy
• Price of BI’s diabetes drug Trajenta is cut 30% from July
• by Lee, Tak-Sun Jun 24, 2024 05:46am

• Company
• Pfizer reapplies for reimb listing of Vyndamax in Korea
• by Eo, Yun-Ho Jun 21, 2024 05:47am

• Policy
• Low-dose 'nicergoline' is increasingly becoming available
• by Lee, Hye-Kyung Jun 21, 2024 05:47am

• Company
• AprilBio licenses out novel drug to a U.S. firm
• by Son, Hyung-Min Jun 21, 2024 05:47am

• Policy
• DLBCL treatment Epkinly is approved in Korea
• by Lee, Hye-Kyung Jun 21, 2024 05:47am